Skip to main content

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Publication ,  Journal Article
Cokgor, I; Akabani, G; Kuan, CT; Friedman, HS; Friedman, AH; Coleman, RE; McLendon, RE; Bigner, SH; Zhao, XG; Garcia-Turner, AM; Pegram, CN ...
Published in: J Clin Oncol
November 15, 2000

PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any objective responses with this treatment. PATIENTS AND METHODS: In this phase I trial, newly diagnosed patients with malignant gliomas with no prior external-beam therapy or chemotherapy were treated with a single injection of (131)I-labeled 81C6 through a Rickham reservoir into the resection cavity. The initial dose was 20 mCi and escalation was in 20-mCi increments. Patients were observed for toxicity and response until death or for a minimum of 1 year after treatment. RESULTS: We treated 42 patients with (131)I-labeled 81C6 mAb in administered doses up to 180 mCi. Dose-limiting toxicity was observed at doses greater than 120 mCi and consisted of delayed neurotoxicity. None of the patients developed major hematologic toxicity. Median survival for patients with glioblastoma multiforme and for all patients was 69 and 79 weeks, respectively. CONCLUSION: The MTD for administration of (131)I-labeled 81C6 into the SCRC of newly diagnosed patients with no prior radiation therapy or chemotherapy was 120 mCi. Dose-limiting toxicity was delayed neurologic toxicity. We are encouraged by the survival and toxicity and by the low 2.5% prevalence of debulking surgery for symptomatic radiation necrosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

November 15, 2000

Volume

18

Issue

22

Start / End Page

3862 / 3872

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Tenascin
  • Survival Analysis
  • Supratentorial Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice, Nude
  • Mice
  • Male
  • Magnetic Resonance Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cokgor, I., Akabani, G., Kuan, C. T., Friedman, H. S., Friedman, A. H., Coleman, R. E., … Bigner, D. D. (2000). Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol, 18(22), 3862–3872. https://doi.org/10.1200/JCO.2000.18.22.3862
Cokgor, I., G. Akabani, C. T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.J Clin Oncol 18, no. 22 (November 15, 2000): 3862–72. https://doi.org/10.1200/JCO.2000.18.22.3862.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000 Nov 15;18(22):3862–72.
Cokgor, I., et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.J Clin Oncol, vol. 18, no. 22, Nov. 2000, pp. 3862–72. Pubmed, doi:10.1200/JCO.2000.18.22.3862.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, Zalutsky MR, Bigner DD. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000 Nov 15;18(22):3862–3872.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

November 15, 2000

Volume

18

Issue

22

Start / End Page

3862 / 3872

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Tenascin
  • Survival Analysis
  • Supratentorial Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice, Nude
  • Mice
  • Male
  • Magnetic Resonance Imaging